... Sciences, Inc.,Rockville, MA, USA) is a recombinant, fully human, IgG1λ mAbthat binds to soluble BLyS with high affinity. The antibodyexerts its biologic activity by preventing the binding of BLyS ... emergent if they occurred within84 days after the final dose of study agent (day 84 for single-dose cohorts and day 105 for double-dose cohorts). Hematol-ogy, clinical chemistry, and urinalysis panels ... potently inhibits BLyS-inducedproliferation of B cells in vitro and prevents human BLyS-induced increases in splenic B-cell numbers and serum IgA tit-ers in mice [19]. In cynomolgus monkeys treated...